Skip to main content

Table 3 Summary of Mixed Model Results for PCM Items and PCM Index Scores

From: Retrospective study of the effect of disease progression on patient reported outcomes in HER-2 negative metastatic breast cancer patients

  Mixed Model Results
Endpoint Change over time since Diagnosis
(Interval)
Change at Disease Progression
(Progression)
Change with Proximity to Progression
(Proximity)
Main or Interaction Effects
involving Regimen Group a
PCM Items     
   Fatigue Improving (p = .02) Worsened (p = .004) No effect Progression: H = NT > T (p = .052)b
   Pain No effect Worsened (p = .051) No effect No effect
   Trouble Sleeping No effect No effect No effect Main effect: H = NT < T (p = .001)
PCM Index Scores     
   General Physical Symptoms Improving (p < .001) Worsened (p < .001) Tended to worsen leading into
progression, with less improvement
leading out (p = .088)
No effect
   Treatment Side Effects Improving (p = .013) Worsened (p < .001) No main effect Proximity: H = NT < T (p = .005) [Taxane had worse scores
distal from progression]
   Acute Distress Improving (p = .002); improving faster
after progression (p = .022)
Worsened (p = .002) No effect No effect
   Despair and Depression No effect No effect No effect No effect
   Impaired Ambulation No effect No effect No effect No effect
   Impaired Performance Improving (p = .003) Worsened (p = .003) No effect Main effect: H < NT (p = .005) > T (p = .004)
  1. aH = Hormone therapy or no therapy, NT = Non-taxane based regimen, T = Taxane based regimen. Main effect = main effect of Regimen group; Progression = interaction of regimen group with Change at Progression; Proximity = interaction of regimen group with Change with Proximity to Progression. bP values are for specific contrasts involving regimen groups, with Taxane and Hormone only groups tested against the Non-taxane, which was the reference condition. P values for overall regimen effects are reported in the text where significant.